Awakn Life Sciences Corp
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavi… Read more
Awakn Life Sciences Corp (AWKNF) - Net Assets
Latest net assets as of October 2024: $-1.52 Million USD
Based on the latest financial reports, Awakn Life Sciences Corp (AWKNF) has net assets worth $-1.52 Million USD as of October 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($668.81K) and total liabilities ($2.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.52 Million |
| % of Total Assets | -227.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 325.82 |
Awakn Life Sciences Corp - Net Assets Trend (2021–2024)
This chart illustrates how Awakn Life Sciences Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Awakn Life Sciences Corp (2021–2024)
The table below shows the annual net assets of Awakn Life Sciences Corp from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-01-31 | $-1.53 Million | -2976.45% |
| 2023-01-31 | $-49.74K | -101.65% |
| 2022-01-31 | $3.02 Million | +549.99% |
| 2021-01-31 | $465.04K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Awakn Life Sciences Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3009992900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $22.22 Million | % |
| Other Comprehensive Income | $-277.94K | % |
| Other Components | $7.49 Million | % |
| Total Equity | $-1.53 Million | 100.00% |
Awakn Life Sciences Corp Competitors by Market Cap
The table below lists competitors of Awakn Life Sciences Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scinai Immunotherapeutics Ltd
NASDAQ:SCNI
|
$2.37 Million |
|
GREEN SHIFT COMMODITIES
F:7WV
|
$2.37 Million |
|
Mekong Fisheries JSC
VN:AAM
|
$2.37 Million |
|
Bounty Oil & Gas NL
PINK:BYOGF
|
$2.38 Million |
|
THALES - Dusseldorf Stock Exchang
DU:CSF
|
$2.37 Million |
|
Simble Solutions Ltd
AU:SIS
|
$2.37 Million |
|
Sadot Group Inc.
NASDAQ:SDOT
|
$2.37 Million |
|
Tianrong Internet Products and Services Inc
PINK:TIPS
|
$2.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Awakn Life Sciences Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 847,738 to -1,530,289, a change of -2,378,027 (-280.5%).
- Net loss of 5,102,704 reduced equity.
- New share issuances of 2,656,014 increased equity.
- Other comprehensive income decreased equity by 7,071,831.
- Other factors increased equity by 7,140,494.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.10 Million | -333.45% |
| Share Issuances | $2.66 Million | +173.56% |
| Other Comprehensive Income | $-7.07 Million | -462.12% |
| Other Changes | $7.14 Million | +466.61% |
| Total Change | $- | -280.51% |
Book Value vs Market Value Analysis
This analysis compares Awakn Life Sciences Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-01-31 | $0.03 | $0.07 | x |
| 2022-01-31 | $0.16 | $0.07 | x |
| 2023-01-31 | $0.03 | $0.07 | x |
| 2024-01-31 | $-0.05 | $0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Awakn Life Sciences Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5840.14%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-482.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -384.54% | 0.00% | 0.00x | 2.52x | $-1.29 Million |
| 2022 | -467.46% | -6755.65% | 0.03x | 2.02x | $-16.29 Million |
| 2023 | -1078.46% | -611.40% | 0.34x | 5.18x | $-9.23 Million |
| 2024 | 0.00% | -5840.14% | 0.16x | 0.00x | $-4.95 Million |
Industry Comparison
This section compares Awakn Life Sciences Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Awakn Life Sciences Corp (AWKNF) | $-1.52 Million | -384.54% | N/A | $2.37 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |